Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Plasma metabolization micromolecule marker related to human non-small-cell lung cancer and application of plasma metabolization micromolecule marker

A technology for non-small cell lung cancer and metabolic small molecules, which is applied in the fields of analytical chemistry and clinical medicine, can solve problems such as complex experimental steps, low sensitivity, and narrow detection dynamic range, so as to improve sensitivity and specificity, facilitate detection, and avoid Effect of Invasive Diagnostics

Inactive Publication Date: 2015-12-30
JIANGSU PROVINCE HOSPITAL
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

NMR is characterized by no damage to the components to be measured, simple sample pretreatment, but low sensitivity and narrow detection dynamic range; GC-MS has good sensitivity and reproducibility, but derivatization methods are generally used for sample pretreatment , making the experimental steps more complicated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Plasma metabolization micromolecule marker related to human non-small-cell lung cancer and application of plasma metabolization micromolecule marker
  • Plasma metabolization micromolecule marker related to human non-small-cell lung cancer and application of plasma metabolization micromolecule marker
  • Plasma metabolization micromolecule marker related to human non-small-cell lung cancer and application of plasma metabolization micromolecule marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] Example 1 Research object selection and grouping basis

[0074] The inventors collected blood samples from patients with non-small cell lung cancer and healthy controls that met the requirements from the First Affiliated Hospital of Nanjing Medical University from October 2011 to June 2014. of 112 healthy controls (mean age: 58.5 years, range 42-80 years) and 99 patients with non-small cell lung cancer (mean age: 59.5 years, range 42-83 years) as metabolic small molecule biomarkers for non-small cell lung cancer Object screening test objects. The specific sample classification standards are as follows:

[0075] Group A: healthy control group (n=112, 56 people were screened, 56 people were independently verified):

[0076] 1. Aged between 42 and 80 years old;

[0077] 2. No tumor was diagnosed by physical examination, and there was no previous history of tumor;

[0078] 3. No other major systemic diseases;

[0079] 4. No history of chronic disease with long-term med...

Embodiment 2

[0085] Example 2 The main diagnostic basis of the research object

[0086] The study aimed at patients who were initially diagnosed with non-small cell lung cancer by biopsy, biopsy, and cytopathology, and who had not undergone surgery, radiotherapy, or chemotherapy. The main diagnosis is based on: (1) chest CT imaging findings: see figure 2 ; (2) Results of puncture, biopsy, cytology and pathology: see figure 1 .

[0087] The above clinical examination methods all have their limitations. Among them, chest CT has high false-negative and false-positive results in the diagnosis of lung cancer, and radiological methods have certain radiation damage to lung cancer patients. Puncture, biopsy, and cytology methods are more accurate, but they are invasive diagnostic methods, and the patient is in the middle and late stages at the time of diagnosis, and the disease cannot be detected early. In clinical work, more patients are diagnosed by pathological examination of surgically resec...

Embodiment 3

[0088] Example 3 UPLC-MS Metabolomics Non-Small Cell Lung Cancer Biomarker Screening

[0089] 1. Sample pretreatment

[0090] 1. Centrifuge the fresh blood at 3000 rpm for 5 min, and dispense 400 μl of the supernatant into clean 1.5 ml EP tubes.

[0091] 2. 400 μl of plasma was used to precipitate proteins with 1200 μl of methanol.

[0092] 3. Aspirate the supernatant, divide into 2 equal parts, blow dry with nitrogen and then dry under vacuum.

[0093] 4. Dissolve one portion of the dry matter (acidic extract) with 50 μL of water (containing 0.1% formic acid) and the other dry matter with 50 μL of water containing 6.5 mM ammonium bicarbonate pH=8 (alkaline extract).

[0094] 2. Instrument testing

[0095] 2.1 Analytical instrument: UPLC tandem ThermoFisherLTQ-FT linear ion trap cyclotron resonance mass spectrometer of WatersAcquity Company was used.

[0096] 2.2 Liquid phase conditions:

[0097] 2.2.1 The liquid chromatography column is WatersBEHC181.7μm100mm chromatogra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of analytical chemistry and clinical medicine and relates to a plasma metabolization micromolecule marker related to the human non-small-cell lung cancer and an application of the plasma metabolization micromolecule marker. The plasma metabolization micromolecule marker related to the human non-small-cell lung cancer is one or more of cortisol, corticosterone and 4-methoxyphenylacetic acid. The plasma metabolization micromolecule marker is prepared from cortisol, corticosterone and 4-methoxyphenylacetic acid. The content range (95% confidence interval) of cortisol is 0.00018-0.00067, the content range (95% confidence interval) of corticosterone is 0.000029-0.00010, the content range (95% confidence interval) of 4-methoxyphenylacetic acid is 0.000015-0.000022, and metabolite can prompt occurrence of tumors within the ranges. The horizontal range, corresponding to a normal group, of cortisol is 0.0030-0.0037, the horizontal range, corresponding to the normal group, of corticosterone is 0.00044-0.00056, and the horizontal range, corresponding to the normal group, of 4-methoxyphenylacetic acid is 7.39 E-07-2.09 E-06. The plasma metabolization micromolecule marker is a novel biomarker, compared with a traditional protein biomarker, the relevance between the marker and the disease outcome is higher, and the plasma metabolization micromolecule marker is stable, minimally invasive, easy to detect and accurate in quantitation.

Description

Field of Invention [0001] The invention belongs to the fields of analytical chemistry and clinical medicine, and relates to a plasma metabolic small molecule marker related to human non-small cell lung cancer and its application. Background technique [0002] Lung cancer is the most common cause of cancer-related death in both men and women worldwide. It is estimated that there were 18 million new cases of lung cancer worldwide in 2012, accounting for 12.9% of all new cancer cases, and 16 million deaths, accounting for 19.4% of all cancer-related deaths. Lung cancer is divided into non-small cell lung cancer and small cell lung cancer (15%) according to cell type. There are two main subtypes of non-small cell lung cancer, adenocarcinoma (40%) and squamous cell carcinoma (30%), depending on the type Its treatment and prognosis also vary. [0003] At present, the imaging methods used in clinical diagnosis of lung cancer include chest X-ray, computed tomography (CT), and PET-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/88
Inventor 郭人花向程程冯静夏彦恺金时代束永前
Owner JIANGSU PROVINCE HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com